HCC1954 Orthotopic Mouse Model Service for Breast Cancer

The HCC1954 orthotopic xenograft model recapitulates the aggressive biology of human HER2-positive breast cancer—complete with PI3K pathway hyperactivation, trastuzumab resistance, and spontaneous mammary tumor growth—in an immunodeficient host that supports authentic human tumor–stroma interactions. Alfa Cytology engineers and manages every phase of this model, from authenticated cell banking and orthotopic surgical implantation in NSG mice through longitudinal tumor monitoring and molecular endpoint characterization, giving your anti-HER2 or PI3K-targeted program the translational foundation it requires.

Overview of HCC1954 Orthotopic Mouse Model for Breast Cancer

HCC1954 is a human breast cancer cell line originally established from the primary tumor of a patient diagnosed with grade 3, stage IIA invasive ductal carcinoma with no lymph node involvement at the time of resection. At the molecular level, the line is defined by robust HER2 (ERBB2) amplification and protein overexpression, rendering it a canonical representative of the HER2-enriched breast cancer subtype. Concurrently, HCC1954 harbors an activating PIK3CA H1047R hotspot mutation and a TP53 Y163C missense mutation—two alterations that frequently co-occur in clinical HER2-positive disease and collectively drive constitutive PI3K–AKT–mTOR signaling, genomic instability, and therapeutic escape. Notably, HCC1954 exhibits intrinsic resistance to trastuzumab monotherapy in vitro, mirroring the clinical challenge of de novo resistance that affects a subset of HER2-positive patients and making this model indispensable for dissecting resistance mechanisms and testing next-generation therapeutic strategies such as PI3K inhibitors, tyrosine kinase inhibitors, and antibody–drug conjugates.

Fig 1. 18F-FDG PET analysis of the HCC1954 orthotopic surgical resection model of Her2⁺ breast cancer following PT vs PTB treatment. (Miller, Ian S., et al., 2019)

When propagated as an orthotopic xenograft in severely immunodeficient mice—most commonly NOD-scid-IL2Rγnull (NSG) or NOD-SCID strains—HCC1954 cells engraft into the mammary fat pad and recapitulate the architectural and growth dynamics of human HER2-positive breast tumors within a host microenvironment that, while lacking adaptive immunity, retains fundamental stromal and vascular components. The orthotopic context is critical: tumors develop within the native mammary gland basement membrane, engaging physiologically relevant ECM interactions and paracrine signaling loops that are absent in subcutaneous alternatives. Tumors typically become palpable within 2–4 weeks and exhibit aggressive local expansion. This model has been widely adopted for evaluating anti-HER2 antibody–drug conjugates, dual HER2 blockade regimens, PI3Kα-selective inhibitors, and combination schedules that seek to overcome PI3K-driven resistance—positioning HCC1954 as a cornerstone cell line for translational breast cancer pharmacology.

Cell Line Information: HCC1954

HCC1954 is a well-characterized human breast carcinoma cell line maintained by major biorepositories and extensively profiled through genomic, transcriptomic, and proteomic platforms. Its co-occurring HER2 amplification and PIK3CA mutation make it a biologically faithful surrogate for a significant subset of treatment-refractory HER2-positive breast cancers. The table below details the essential characteristics of HCC1954 as applied in orthotopic xenograft preclinical research.

Our Services

Alfa Cytology maintains HCC1954 under rigorous cell banking standards, including routine mycoplasma testing, short tandem repeat (STR) authentication against the ATCC reference profile, and passage-number tracking to preserve genetic fidelity. Our NSG vivarium operates under IACUC-approved protocols with continuous health monitoring, ensuring that every orthotopic implantation yields consistent tumor take rates and pharmacologically relevant growth kinetics for your HER2-targeted or PI3K-directed preclinical program.

Workflow of HCC1954 Orthotopic Mouse Model Construction

Establishing the HCC1954 orthotopic xenograft demands meticulous coordination between cell culture quality assurance, surgical precision in immunodeficient hosts, and standardized tumor monitoring protocols. Because HCC1954 is a human cell line propagated in mice lacking functional T, B, and NK cells, every step—from cell authentication to endpoint necropsy—must be executed under aseptic conditions to prevent opportunistic infection and data corruption. The workflow below outlines our validated protocol.

1. Cell Authentication & Expansion: HCC1954 cells are thawed from a master cell bank verified by STR profiling against the ATCC reference standard and confirmed negative for mycoplasma by PCR. Cells are expanded in antibiotic-supplemented RPMI-1640 + 10% FBS, with passage number strictly limited to maintain phenotypic stability. HER2 expression is periodically confirmed by flow cytometry or immunofluorescence to ensure retention of the target antigen prior to in vivo use.
2. Cell Harvest & Matrix Preparation: On the day of implantation, subconfluent HCC1954 cells are detached with trypsin-EDTA, washed twice in sterile PBS, and counted via hemocytometer with trypan blue viability assessment. The final cell suspension is prepared at 2 × 10⁷ cells/ml in ice-cold PBS and mixed 1:1 (v/v) with chilled, phenol red–free basement membrane matrix to achieve a final concentration of 1 × 10⁷ cells per 100 µl. The matrix–cell mixture is kept on ice until injection to prevent premature polymerization.
3. Animal Preparation & Anesthesia: Female NSG mice aged 6–10 weeks are housed in individually ventilated cages within a barrier facility and acclimatized for a minimum of 5–7 days. On the procedure day, mice are anesthetized with isoflurane (2–3% in medical oxygen) delivered via precision vaporizer and nose cone. The lower abdominal surgical field is shaved and sequentially sterilized with povidone-iodine and 70% ethanol.
4. Orthotopic Mammary Fat Pad Implantation: A 100 µl suspension containing 1–5 × 10⁶ HCC1954 cells in basement membrane matrix is drawn into a ½ cc insulin syringe fitted with a 25 G needle. The needle is inserted tangentially into the 4th inguinal mammary fat pad, and the cell-matrix mixture is deposited slowly within the glandular stroma. The needle is held in place for 10 seconds post-injection to minimize reflux, and the skin incision is closed with surgical adhesive or a single wound clip. Mice are recovered on a heated pad under continuous observation until fully ambulatory.
5. Post-Operative Monitoring & Tumor Surveillance: Mice are monitored daily for the first 72 hours post-surgery for signs of pain, distress, or wound complications. Beginning at day 7, tumor dimensions are measured twice weekly with digital calipers, and tumor volume is calculated using the modified ellipsoid formula (length × width² × 0.5). Body weights and clinical scores are recorded at each measurement interval to ensure compliance with humane endpoint criteria.
6. Therapeutic Intervention & Dosing: Once tumors reach a protocol-defined size—commonly 100–200 mm³—mice are randomized into treatment cohorts. Investigational agents (e.g., anti-HER2 antibodies, PI3Kα inhibitors, ADCs, or combination regimens) are administered according to the study design, with dosing schedules tailored to the pharmacokinetic profile of each compound. Vehicle controls receive matched formulation on an identical schedule.
7. Longitudinal Tumor Response Assessment: Tumor growth is tracked until tumors in the vehicle group approach institutional size limits (typically ~2,000 mm³ or 8 weeks post-implantation). Tumor growth inhibition (TGI) is calculated from caliper-derived volume curves, and individual mouse responses are categorized as partial response, stable disease, or progressive disease based on percent change from baseline volume.
8. Terminal Endpoint & Molecular Characterization: At study termination, mice are euthanized and primary tumors are excised en bloc, weighed, and photographed. Tumor tissue is snap-frozen in liquid nitrogen for Western blot or RNA analysis, fixed in 10% neutral buffered formalin for paraffin embedding and H&E staining, and subjected to immunohistochemistry for Ki67, cleaved caspase-3, phospho-AKT, phospho-S6, and HER2 expression. Plasma may be collected for pharmacokinetic analysis, and any macroscopic lesions in distant organs are documented.

Fig 2. HCC1954 Orthotopic Mouse Model construction workflow.

Case Study-HCC1954 Orthotopic Mouse Model Development

In a recent preclinical engagement, Alfa Cytology established an orthotopic HCC1954 xenograft to evaluate the efficacy of a novel PI3Kα-selective inhibitor administered in combination with an anti-HER2 antibody–drug conjugate. Following mammary fat pad implantation of HCC1954 cells in NSG mice, tumor-bearing animals were randomized once tumors reached approximately 150 mm³. The combination regimen was delivered over a 3-week treatment window, with tumor volumes measured twice weekly and terminal tumors analyzed for PI3K pathway biomarkers. The combination cohort demonstrated substantially greater tumor growth inhibition relative to either monotherapy arm, with immunohistochemical analysis revealing marked suppression of phospho-AKT and phospho-S6 signaling in residual tumor tissue. These findings provided preclinical rationale for advancing the combination into subsequent IND-enabling studies, underscoring the translational value of the HCC1954 model in capturing PI3K-driven resistance to HER2-directed therapy.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your HCC1954 orthotopic program means partnering with a CRO that understands the molecular nuances of HER2-positive disease and the operational complexities of human xenograft work in immunodeficient hosts. Our infrastructure is purpose-built to deliver data that bridges the gap between cell-based assays and clinical proof-of-concept.

• HCC1954 master cell banks are authenticated by STR profiling, mycoplasma PCR, and periodic HER2 expression validation to ensure antigen fidelity and genetic stability across all study cohorts.
• Our NSG vivarium maintains stringent barrier conditions with continuous health surveillance, minimizing the infection risk that can compromise immunodeficient xenograft studies.
• Surgical teams are proficient in orthotopic mammary fat pad implantation with basement membrane matrix, achieving high tumor take rates and consistent growth kinetics in HCC1954 xenografts.
• Integrated biomarker capabilities—including phospho-AKT, phospho-S6, Ki67, and cleaved caspase-3 IHC—allow mechanistic interpretation of drug response directly from tumor tissue collected at study termination.
• Flexible study designs accommodate single-agent, combination, and sequential dosing arms with pharmacokinetic blood sampling and plasma drug concentration analysis available on request.
• All protocols are developed and executed under IACUC oversight with AAALAC-aligned standards, producing audit-ready documentation suitable for IND-enabling packages and regulatory submissions.
• Project managers provide biweekly data packages, interim statistical summaries, and real-time protocol amendments, ensuring transparent communication and the agility to pivot as pharmacological findings emerge.

Contact Us

If your preclinical pipeline demands a human-relevant HER2-positive breast cancer model that captures the PI3K-driven resistance biology seen in the clinic, the HCC1954 orthotopic xenograft at Alfa Cytology offers the translational rigor your compound deserves. Reach out to us today to discuss your study design, review our HCC1954 quality control dossier, and receive a tailored proposal with timeline, dosing schema, and endpoint package options aligned with your anti-HER2 or PI3K-targeted development strategy.

For research use only. Not intended for any clinical use.